U.S. panel split on Pfizer rare disease drug

U.S. panel split on Pfizer rare disease drug
(Reuters) - A U.S. health advisory panel on Thursday issued a split vote on data for Pfizer Inc's drug to treat a rare neurodegenerative disease. The U.S. Food and Drug Administration panel voted 13 to 4 that the drug did not show that it met the main goal in a study in treating the fatal condition. However, the panel also voted 13 to 4 that the drug treated a surrogate endpoint, which may correlate with treating the underlying disease. The panel's recommendation will be considered by the U.S. ...
Source: news.yahoo.com